shutterstock-163310765-3

Andy P / Shutterstock.com

30 May 2014Europe

Imanova: investing in know-how

Given the spiralling costs and ever-present risks associated with developing a new drug, pharmaceutical companies are always looking for ways to shorten the pathway from lab bench to clinic.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

CREATES Act unfairly tips the scales to generics

UPC deals further blow to Dexcom in glucose monitor dispute with Abbott

LSPN Europe: Navigating the EPO and lessons from the UPC frontline

Paul Hastings reinforces London office with high-tech patent litigator

Comparing life sciences IP in Brazil and the US

EPO invalidates human milk patent after Nestle opposition

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

GSK triumphs in EPO appeal, revoking Pfizer patent